0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CXADR

CXADR

Brief Information

Name:Calcium sensing receptor
Target Synonym:Extracellular calcium-sensing receptor,hCasR,GPRC2A,Calcium Sensing Receptor,Parathyroid Ca(2+)-Sensing Receptor 1,Severe Neonatal Hyperparathyroidism,Calcium-Sensing Receptor,HYPOC1,NSHPT,PCaR1,EIG8,HHC1,CaSR,CAR,FHH,FIH,HHC,Receptors, Calcium-Sensing,Hy
Number of Launched Drugs:5
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CXR-H5222 Human Human CXADR / CAR Protein, His Tag
CXR-H5222-structure
CXR-H5222-sds

Synonym Name

CXADR,CAR,CAR4/6,HCAR

Background

Coxsackie virus and adenovirus receptor (CXADR) is also known as CAR, is a type I transmembrane glycoprotein for group B coxsackie viruses and subgroup C adenoviruses, and belongs to the CTX family of the Ig superfamily. CAR is strongly expressed in the developing central nervous system. It functions as a homophilic and also as a heterophilic cell adhesion molecule through its interactions with extracellular matrix glycoproteins such as: fibronectin, agrin, laminin-1 and tenascin-R. Human

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Evocalcet MT-4580; KHK-7580 Approved Mitsubishi Tanabe Pharma Corp Orkedia Japan Hyperparathyroidism, Secondary Kyowa Hakko Kirin 2018-03-23 Hyperparathyroidism, Secondary; Parathyroid Neoplasms; Hyperparathyroidism, Primary; Hyperparathyroidism Details
Parathyroid hormone (Shire) 423562; ALX-111; SHP-634; SHP-635; NPSP-558; NPSP-795; PTH 1-84; SB-423562; PTH (1-84); rhPTH-1-84; rhPTH (1-84) Approved Shire Natpar, Natpara, Preotact EU Hypoparathyroidism Shire Pharmaceuticals Ireland Ltd 2006-04-24 Osteoporosis; Osteoporosis, Postmenopausal; Hypoparathyroidism Details
Upacicalcet SK-1403; AJT-240 Approved Ea Pharma Upasita Japan Hyperparathyroidism, Secondary Sanwa Kagaku Kenkyusho 2021-06-23 Hyperparathyroidism, Secondary; Hyperparathyroidism Details
Etelcalcetide Hydrochloride AMG-416; KAI-4169; KAI-4169-HCl; ONO-5163 Approved Amgen Inc Parsabiv United States Hyperparathyroidism, Secondary Kai Pharmaceuticals 2016-11-11 Hyperparathyroidism, Secondary; Edema, Cardiac; Renal Insufficiency, Chronic Details
Cinacalcet Hydrochloride AMG-073; KRN-1493; NPS-1493; AMG-073.HCl Approved Amgen Inc 盖平, Mimpara, Parareg, Regpara, Sensipar, Sensipar/Mimpara Mainland China Hypercalcemia; Hyperparathyroidism; Hyperparathyroidism, Secondary Kyowa Hakko Kirin 2004-03-08 Hyperparathyroidism, Secondary; Rejection of renal transplantation; Parathyroid Neoplasms; Hypophosphatemia; Nephrosis; Edema, Cardiac; Hypercalcemia; Kidney Diseases; Hyperparathyroidism, Primary; Renal Insufficiency, Chronic; Kidney Failure, Chronic; Hyperparathyroidism; Chronic Kidney Disease-Mineral and Bone Disorder Details
Strontium Ranelate FK-481; S-12911; S-12911-2 Approved Servier 欧思美, Osseor, Protos, Protelos Mainland China Osteoporosis, Postmenopausal Les Laboratoires Servier 2004-09-20 Osteoporosis, Postmenopausal Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
LNP-1892 LNP-1892 Phase 2 Clinical Rubin Ltd Hyperparathyroidism Details
Encaleret sulfate MK-5442; JTT-305; CLTX-305 Phase 2 Clinical Japan Tobacco (Hong Kong) Ltd Osteoporosis; Hypocalcemia; Osteoporosis, Postmenopausal Details
DS-9194b DS-9194b Phase 1 Clinical Daiichi Sankyo Co Ltd Osteoporosis Details

This web search service is supported by Google Inc.

totop